Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 18-May-22 6:01 PM View:  | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 18-May-22 | Private Purchase | 20,000 | $0.44 | $8,866.00 | 29% 70.09K to 90.09K | |
| 18-May-22 6:02 PM View: | Straube Richard SENIOR VICE PRESIDENT AND CMO | DOR BioPharma, Inc. (SNGX) | 18-May-22 | Private Purchase | 8,000 | $0.50 | $4,000.00 | 100% 0 to 8.0K | |
| 20-Dec-21 4:23 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 17-Dec-21 | Market Purchase | 7,000 | $0.74 | $5,179.30 | 11% 63.09K to 70.09K | 1% |
| 15-Dec-21 4:05 PM View: | Guarino Jonathan L. Senior Vice President and CFO | DOR BioPharma, Inc. (SNGX) | 15-Dec-21 | Market Purchase | 1,000 | $0.70 | $700.00 | 10% 10.0K to 11.0K | 0% |
| 15-Dec-21 7:20 AM View: | Guarino Jonathan L. Senior Vice President and CFO | DOR BioPharma, Inc. (SNGX) | 14-Dec-21 | Market Purchase | 10,000 | $0.71 | $7,119.00 | 100% 0 to 10.0K | (2%) |
| 14-Dec-21 4:05 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 14-Dec-21 | Market Purchase | 10,000 | $0.73 | $7,269.00 | 19% 53.09K to 63.09K | 3% |
| 18-May-21 5:00 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 14-May-21 | Market Purchase | 3,000 | $0.89 | $2,664.00 | 13% 22.92K to 25.92K | |
| 18-May-21 5:00 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 14-May-21 | Market Sale | 3,000 | $0.90 | $2,700.60 | (12%) 25.92K to 22.92K | |
| 19-Nov-19 4:19 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 19-Nov-19 | Market Purchase | 2,000 | $0.93 | $1,850.00 | 10% 20.92K to 22.92K | 44% |
| 19-Nov-19 4:18 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 19-Nov-19 | Market Purchase | 10,770 | $0.93 | $10,016.10 | 25% 42.33K to 53.09K | 43% |
| 23-Sep-19 7:15 PM View: | Parks Diane L. Director | DOR BioPharma, Inc. (SNGX) | 23-Sep-19 | Market Purchase | 14,940 | $0.93 | $13,870.30 | 100% 0 to 14.94K | 42% |
| 23-Sep-19 4:19 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 19-Sep-19 | Market Purchase | 4,000 | $0.94 | $3,740.00 | 24% 16.92K to 20.92K | 44% |
| 10-Jul-19 5:21 PM View: | Pearson Mark E. Director 10% Owner | DOR BioPharma, Inc. (SNGX) | 28-Jun-19 | Grant | 78,338 | $0.71 | $55,620.00 | 3% 2.5M to 2.58M | 94% |
| 22-Apr-19 4:41 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 22-Apr-19 | Market Purchase | 10,000 | $0.73 | $7,274.00 | 145% 6.92K to 16.92K | 89% |
| 22-Apr-19 4:41 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 22-Apr-19 | Market Purchase | 5,000 | $0.72 | $3,577.00 | 13% 37.33K to 42.33K | 93% |
| 18-Oct-18 4:51 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 18-Oct-18 | Market Purchase | 8,700 | $1.17 | $10,177.30 | 30% 28.63K to 37.33K | 21% |
| 17-Oct-18 8:09 PM View: | Pearson Mark E. Director | DOR BioPharma, Inc. (SNGX) | 17-Oct-18 | Market Purchase | 170,000 | $1.16 | $197,200.00 | 7% 2.33M to 2.5M | 20% |
| 22-Aug-18 5:00 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 22-Aug-18 | Market Purchase | 3,530 | $1.42 | $5,011.89 | 14% 25.09K to 28.63K | (1%) |
| 01-Dec-17 4:25 PM View: | Sigma Tau Finanziaria Spa | DOR BioPharma, Inc. (SNGX) | 29-Nov-17 | Market Purchase | 293,510 | $2.12 | $622,241.00 | 35% 841.74K to 1.14M | (34%) |
| 01-Dec-17 4:25 PM View: | Sigma Tau Finanziaria Spa | DOR BioPharma, Inc. (SNGX) | 29-Nov-17 | Market Sale | 293,510 | $2.12 | $622,241.00 | (26%) 1.14M to 841.74K | 34% |
| 08-May-17 5:30 PM View: | Kirk Randal J 10% Owner | DOR BioPharma, Inc. (SNGX) | 08-May-17 | Market Sale | 11,576 | $2.54 | $29,403.00 | (2%) 537.39K to 525.82K | 45% |
| 08-May-17 5:30 PM View: | Kirk Randal J 10% Owner | DOR BioPharma, Inc. (SNGX) | 05-May-17 | Market Sale | 85,500 | $2.70 | $230,850.00 | (14%) 622.89K to 537.39K | 48% |
| 08-May-17 5:30 PM View: | Kirk Randal J 10% Owner | DOR BioPharma, Inc. (SNGX) | 04-May-17 | Private Sale | 63,892 | $3.78 | $241,629.00 | (9%) 686.78K to 622.89K | |
| 08-May-17 5:30 PM View: | Kirk Randal J 10% Owner | DOR BioPharma, Inc. (SNGX) | 04-May-17 | Exercise (in-the money or at-the-money) | 250,000 | $0.80 | $200,000.00 | 57% 436.78K to 686.78K | |
| 20-Dec-16 10:00 AM View: | Brughera Marco Maria Director | DOR BioPharma, Inc. (SNGX) | 16-Dec-16 | Purchase | 2,000 | $3.16 | $6,319.80 | 267% 0.75K to 2.75K | (70%) |
| 20-Dec-16 10:01 AM View: | Rubin Robert Joseph Director | DOR BioPharma, Inc. (SNGX) | 16-Dec-16 | Purchase | 3,165 | $3.16 | $10,001.10 | 259% 1.22K to 4.38K | (70%) |
| 20-Dec-16 10:02 AM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 16-Dec-16 | Purchase | 15,804 | $3.16 | $49,939.10 | 170% 9.29K to 25.09K | (70%) |
| 23-Dec-15 10:04 AM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 23-Dec-15 | Market Purchase | 2,500 | $1.27 | $3,175.00 | 4% 66.67K to 69.17K | (88%) |
| 23-Dec-15 6:02 AM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 22-Dec-15 | Market Purchase | 10,000 | $1.29 | $12,878.00 | 13% 75.76K to 85.76K | (88%) |
| 31-Aug-15 5:03 PM View: | Lapointe Gregg Anthony Director | DOR BioPharma, Inc. (SNGX) | 31-Aug-15 | Option Exercise | 25,000 | $0.30 | $7,500.00 | 51% 48.78K to 73.78K | |
| 01-Jul-15 7:16 AM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 01-Jul-15 | Option Exercise | 7,143 | $0.61 | $4,357.23 | 9% 75.76K to 82.9K | |
| 09-Apr-15 6:50 PM View: | Brownlie Keith L Director | DOR BioPharma, Inc. (SNGX) | 09-Apr-15 | Option Exercise | 14,286 | $0.61 | $8,714.46 | 40% 35.71K to 50.0K | |
| 09-Apr-15 6:52 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 09-Apr-15 | Option Exercise | 17,857 | $0.61 | $10,892.80 | 37% 48.81K to 66.67K | |
| 24-Dec-14 10:06 AM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 22-Dec-14 | Purchase | 8,265 | $1.21 | $10,000.70 | 12% 67.5K to 75.76K | |
| 24-Dec-14 10:05 AM View: | Warusz Joseph Michael VP of Finance/Acting CFO | DOR BioPharma, Inc. (SNGX) | 22-Dec-14 | Purchase | 8,265 | $1.21 | $10,000.70 | 176% 4.69K to 12.96K | |
| 05-Aug-14 2:18 PM View: | Brughera Marco Maria Director | DOR BioPharma, Inc. (SNGX) | 05-Aug-14 | Option Exercise | 7,500 | $2.01 | $15,075.00 | 100% 0 to 7.5K | (92%) |
| 19-May-14 7:30 AM View: | Warusz Joseph Michael VP of Admin, Controller / PAO | DOR BioPharma, Inc. (SNGX) | 19-May-14 | Option Exercise | 4,690 | $0.64 | $3,001.60 | 100% 0 to 4.69K | |
| 16-May-14 7:30 AM View: | Brownlie Keith L Director | DOR BioPharma, Inc. (SNGX) | 14-May-14 | Option Exercise | 16,667 | $0.30 | $5,000.10 | 88% 19.05K to 35.71K | 660% |
| 14-May-14 7:28 AM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 13-May-14 | Option Exercise | 7,815 | $0.64 | $5,001.60 | 13% 59.68K to 67.5K | |
| 26-Jun-13 4:18 PM View: | Schaber Christopher Chairman, CEO and President Director | DOR BioPharma, Inc. (SNGX) | 25-Jun-13 | Market Purchase | 9,523 | $1.05 | $9,999.15 | 19% 50.16K to 59.68K | (85%) |
| 26-Jun-13 4:17 PM View: | Brownlie Keith L Director | DOR BioPharma, Inc. (SNGX) | 25-Jun-13 | Market Purchase | 19,047 | $1.05 | $19,999.30 | 100% 0 to 19.05K | (85%) |
| 26-Jun-13 4:18 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 25-Jun-13 | Market Purchase | 23,809 | $1.05 | $24,999.40 | 95% 25.0K to 48.81K | (85%) |
| 24-Jun-13 7:20 PM View: | Zeldis Jerome B Director | DOR BioPharma, Inc. (SNGX) | 20-Jun-13 | Option Exercise | 25,000 | $0.30 | $7,500.00 | 100% 0 to 25.0K | 660% |
| 11-Apr-12 7:12 PM View: | Schaber Christopher Chairman CEO and President Director | DOR BioPharma, Inc. (SNGX) | 10-Apr-12 | Market Purchase | 9,900 | $0.51 | $5,047.02 | 25% 40.26K to 50.16K | (71%) |
| 18-Jan-12 4:03 PM View: | Schaber Christopher Chairman CEO and President Director | DOR BioPharma, Inc. (SNGX) | 16-Jan-12 | Grant | 333,333 | -- | -- | 71% 471.82K to 805.15K | |
| 20-Aug-10 2:00 PM View: | Bam Management LLC 10% Owner | DOR BioPharma, Inc. (SNGX) | 18-Aug-10 | Market Purchase | 160,000 | $0.24 | $38,400.00 | (< 1%) 21.93M to 21.77M | 92% |
| 20-Aug-10 2:00 PM View: | Bam Management LLC 10% Owner | DOR BioPharma, Inc. (SNGX) | 18-Aug-10 | Market Sale | 192,314 | $0.24 | $46,155.40 | (< 1%) 21.77M to 21.57M | 92% |
| 22-Jun-10 12:11 PM View: | Lapointe Gregg Anthony Director | DOR BioPharma, Inc. (SNGX) | 18-Jun-10 | Private Purchase | 975,610 | $0.20 | $200,000.00 | 100% 0 to 975.61K | |
| 21-Jun-10 4:57 PM View: | Sigma Tau Finanziaria Spa 10% Owner | DOR BioPharma, Inc. (SNGX) | 18-Jun-10 | Private Purchase | 8,608,580 | $0.20 | $1,764,760.00 | 19% 45.62M to 54.23M | |
| 21-Jun-10 4:58 PM View: | Cavazza Paolo 10% Owner | DOR BioPharma, Inc. (SNGX) | 18-Jun-10 | Private Purchase | 11,535,400 | $0.20 | $2,364,760.00 | 24% 47.17M to 58.7M |
